Robert Motzer, MD
Medical Oncology · New York, NYNPI 1164493961
Payments from drug & device makers
Across 1,865 payments — averaging $17,609 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$14.8M
- Pfizer$8.2M
- E.r. Squibb & Sons, L.L.C.$5.5M
- Eisai Inc.$2M
- Exelixis Inc.$851K
- Genentech, Inc.$485K
- plus $830K from 11 others
Across 15 payments — averaging $1219.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$13K
- F. Hoffmann-la Roche AG$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 101 | $14,842,946 |
| Pfizer | 149 | $8,243,579 |
| E.r. Squibb & Sons, L.L.C. | 36 | $5,545,884 |
| Eisai Inc. | 1,101 | $2,043,122 |
| Exelixis Inc. | 162 | $850,549 |
| Genentech, Inc. | 43 | $485,067 |
| Roche Products Limited | 5 | $325,718 |
| AVEO Pharmaceuticals, Inc. | 241 | $284,332 |
| Novartis | 4 | $173,391 |
| Astrazeneca UK Limited | 3 | $20,305 |
| Eli Lilly | 7 | $7,665 |
| Eisai CO., LTD. | 2 | $6,250 |
| F. Hoffmann-la Roche AG | 6 | $5,251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,600 |
| Incyte Corporation | 2 | $2,460 |
| EMD Serono, Inc. | 1 | $1,500 |
| Veloxis Pharmaceuticals, Inc. | 1 | $118 |
How this compares
$32,840,736 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New York
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
- Amy TierstenNew York$17.6M
- Rona YaegerNew York$17.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.